Sanofi-Aventis reported a 64% drop in fourth-quarter net profit due largely to restructuring costs, and said talks with takeover target Genzyme are continuing, furthering months of suspense surrounding the deal.
The Source: Sanofi Quiet on Genzyme Deal
Orexigen said it will cut 23 jobs, resulting in a 40% reduction of its work force, after a recent regulatory rejection of its obesity drug.
World Heart paused enrollment in a study of its Levacor heart pump, pending regulatory approval of refinements to the device.
Elliott Advisers believes Actelion could be an attractive target for big pharma groups. But a standalone Actelion could be worth far more.
Federal officials questioned companies that make six cancer drugs about their failure to complete follow-up studies they promised to conduct in exchange for accelerated approval.
Latest Pharmaceuticals & Biotech HeadlinesFrom Dow Jones Newswires
Research Pharmaceutical & Biotech
View an interactive map that shows you how stocks in the Pharmaceuticals & Biotech sector are doing today, at a glance.
Get in-depth research on Pharmaceuticals & Biotech companies, including complete news and financials, earnings estimates and more.
Dow Jones Industry Tracker - Pharmaceuticals Dow Jones Industry Tracker - Biotechnology
Ask a question about anything you choose, and let readers from the Journal Community answer it.
Share your opinion on WSJ.com's question of the day.
Create an Account:
Help & Information Center:
Foreign Language Editions:
Copyright ©2011 Dow Jones & Company, Inc. All Rights Reserved